Monkeypox Virus Reduction

Dr. Dana Yee M.D, Clinical Pathologist and Medical Director
Innovative Bioanalysis, Inc.
Full Report


To evaluate the efficacy of the NuvaWave handheld UV device against surface Monkeypox, the virus that causes the disease Mpox.


Testing was conducted in a customized rig provided by WellAir in an 11'x11'x8' chamber following BSL-3 standards. The temperature during testing was approximately 75 ±2 (23.9 ±1°C), with a relative humidity of 41%. A hydrophilic glass slide was inoculated with 0.1 mL of 3.65 x 107 TCID50/mL

Monkeypox in viral media and left to air dry for 40 minutes before being placed on the customer-provided rig for testing. Surface collection occurred at 1 and 2 seconds of exposure, with irradiance recorded during each trial.


After 1 second against the Monkeypox virus, the NuvaWave Handheld UV device reduced a starting concentration of 3.65 x 107 TCID50/mL to an average of 1.42 x 107 TCID50/mL. After 2 seconds of UV exposure, recoverable active Monkeypox decreased to 5.71 x 106 TCID50/mL.


The NuvaWave Handheld UV device demonstrated the ability to reduce the Monkeypox virus on a surface, as shown by the 61.01% (0.41 log reduction) gross reduction after 1 second. More prolonged exposure resulted in a higher drop, as observed by the gross reduction of 84.35% (0.81 log reduction) after 2 seconds.

Contact Us

USA Headquarters
3540 Toringdon Way, Suite 200 Charlotte, NC  28277
1 866 508 1118

Ireland Headquarters
DCU Innovation Campus
Old Finglas Road
Glasnevin, Dublin D11 KXN4
+353 1 907 2750